Global Parkinsons Disease Drugs and Therapeutics Market Trends, Applications, Analysis, Growth, and Forecast to 2027

MarketResearch.biz delivers in-depth insights on the global parkinsons disease drugs and therapeutics market in its upcoming report titled, “Global Parkinsons Disease Drugs and Therapeutics Market Trends, Applications, Analysis, Growth, and Forecast to 2027”. The global parkinsons disease drugs and therapeutics market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the global parkinsons disease drugs and therapeutics market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report offers insightful and detailed information regarding the various key players operating in the global parkinsons disease drugs and therapeutics market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global parkinsons disease drugs and therapeutics market report has been segmented on the basis of treatment type, distribution channel, and region.

Request Covid - 19 Impact

Parkinson's disease is a chronic and progressive neurological disorder where the symptoms continue and worsen with time. The primary symptoms include tremor, slow movements, rigidity, and balance difficulties (postural instability). Moreover, parkinsons disease has no available cure, but the drugs, and therapeutics available for the general population can minimize the effects of its signs and symptoms. Furthermore, the treatment options for parkinsons disease include neurological medications, surgeries, and neurostimulation devices.

Increasing incidence of parkinsons disease among the geriatric population, and increasing awareness about parkinsons disease among the general population are key factors driving growth of the global parkinsons disease drugs and therapeutics market. In addition, significant investment by major players, and presence of large number of drugs in pipeline are major factors expected to contribute to growth of the global parkinsons disease drugs and therapeutics market.

However, lack of expertise for early detection and treatment of parkinsons disease is a key restraint for growth of the global parkinsons disease drugs and therapeutics market. Additionally, high cost of treatment, patent expiry on several drugs used for treatment of parkinsons disease, and increase in generic medication are other factors expected to hamper growth of the global parkinsons disease drugs and therapeutics market.

Currently, the market in North America dominates the global parkinsons disease drugs and therapeutics market in revenue terms owing to high prevalence of parkinsons disease, and favorable government reimbursement policies in the region. The market in Europe accounts for second largest revenue share, due to availability of a large patient pool, followed by Asia Pacific. The market in Asia Pacific is expected to witness relatively high growth over the forecast period owing to increasing awareness regarding parkinsons disease and its treatments, increasing government funding for healthcare facilities, and extensive investments made by the major players for R&D in the region.

Market Segmentation:

Global parkinsons disease drugs and therapeutics market segmentation by treatment type:

• Medications
• Medical Devices

Global parkinsons disease drugs and therapeutics market segmentation by distribution channel:

• Hospital pharmacies
• Online pharmacies
• Retail pharmacies
• Drug stores

Global parkinsons disease drugs and therapeutics market segmentation by region:

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America

• GlaxoSmithKline Plc.
• AbbVie
• Acorda Therapeutics Inc.
• Biogen Inc.
• Merck & Co.
• Novartis AG
• Pfizer Inc.
• F-Hoffmann-La Roche Ltd Inc.
• GlaxoSmithKline
• AstraZeneca plc.
• Teva Pharmaceutical Industries Ltd.